TGen professor discusses benefits of whole genome sequencing in study of multiple myeloma

The scientific benefits of whole genome sequencing at the Translational Genomics Research Institute (TGen) will be presented at the 14th International Myeloma Workshop, April 3-7 at the Kyoto International Conference Center.

Dr. Jonathan Keats, head of 's Research Laboratory, will present Discovering the Underlying Genetics of Multiple Myeloma Through at 8:15 a.m. (Kyoto time) April 4, following the conference opening talk.

Multiple myeloma is a pathological description of a disease characterized by the accumulation of in the bone marrow. Dr. Keats' lab at TGen is focused on using new methods to investigate the genomic features of this disease with the goal of identifying genetic events that drive the development, progression, and mediate therapeutic resistance.

"We will show for the first time the integration of DNA and RNA sequencing in multiple myeloma, and how TGen's comprehensive approach to this research has begun to uncover possible that could lead to the underlying causes of this cancer," Dr. Keats said.

Previous studies have identified as many as 10 distinct biological subgroups of multiple myeloma, highlighting the need to identify distinct genetic defects to address each subtype of this disease.

Recent advances in next generation sequencing can now identify nearly all genetics events existing in an individual tumor. Initial studies have focused on whole genome sequencing or exome sequencing and confirmed (TP53, NRAS, KRAS) as well as identified novel mutations (FAM46C and DIS3). In addition, identification of recurrent and the availability of targeted BRAF inhibitors provide an opportunity to translate research findings into clinical practice to benefit patients.

Dr. Keats is one of the key researchers in TGen's Multiple Myeloma Genomics Initiative, funded by the Multiple Myeloma Research Foundation.

"We will present results from the multiple myeloma genomics initiative using paired whole genome and transcriptome sequencing on 84 patient samples and 68 cell lines. The combination of DNA and RNA based sequencing approaches has improved our ability to identify biologically relevant alterations within each sample," Dr. Keats said.

"Additional analysis will improve out understanding of what leads to multiple myeloma and hopefully lead to new and improved classification and prognostic models."

add to favorites email to friend print save as pdf

Related Stories

Researchers sequence multiple myeloma genome in landmark study

Mar 23, 2011

Using new genome sequencing technologies, researchers from the John Theurer Cancer Center at Hackensack University Medical Center joined colleagues from 20 major North American research institutions to publish the first complete ...

First whole-genome lung cancer study set for conference

Jul 06, 2011

A first-of-its-kind study of a patient with lung cancer who never smoked will be presented today by TGen and the Virginia G. Piper Cancer Center at Scottsdale Healthcare at the 14th World Conference on Lung Cancer, July 3-7 ...

Potential new multiple myeloma therapy developed

Jan 06, 2011

A treatment for the incurable blood cancer Multiple Myeloma could be developed in the future if a groundbreaking scientific discovery is applied to new Leeds-based research into the disease.

Recommended for you

New paper describes how DNA avoids damage from UV light

1 hour ago

In the same week that the U.S. surgeon general issued a 101-page report about the dangers of skin cancer, researchers at Montana State University published a paper breaking new ground on how DNA – the genetic code in every ...

Drug target identified for common childhood blood cancer

2 hours ago

In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers at NYU Langone Medical Center report that they have identified ...

User comments